GMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Globus Medical Inc (GMED) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and growth potential outweigh the short-term technical and trading concerns.
The MACD is negative and contracting, RSI is neutral at 32.253, and moving averages are converging. The stock is trading near its support level (S1: 86.369), with resistance at 92.191. Short-term technical indicators suggest a neutral to slightly bearish trend.
Strong financial performance in Q3 2025 with revenue up 22.91% YoY, net income up 129.50% YoY, and EPS up 131.58% YoY.
Positive analyst sentiment with multiple upgrades and raised price targets, including Needham's $112 target and Piper Sandler's $115 target.
Anticipated growth in the MedTech sector driven by innovation and demographic trends.
Short-term technical indicators are neutral to slightly bearish.
No recent news or significant trading trends from hedge funds or insiders.
Stock trend analysis suggests potential short-term downside risk (-4.01% in the next week).
In Q3 2025, Globus Medical reported revenue of $769.05M (up 22.91% YoY), net income of $118.97M (up 129.50% YoY), EPS of 0.88 (up 131.58% YoY), and gross margin of 63.28% (up 21.76% YoY). These figures indicate strong growth and operational efficiency.
Analysts are overwhelmingly positive on GMED, with recent upgrades from Needham, TD Cowen, Piper Sandler, and others. Price targets range from $100 to $115, reflecting confidence in the company's growth potential and operational improvements.
